

On page 41, lines 22-23, please delete "(SEQ ID NO:11)" and insert therefor --(SEQ ID NO:10)--.

On page 42, line 20, please delete "(SEQ ID NO:10)" and insert therefor --(SEQ ID NO:9)--.

On page 42, line 28, please delete "(SEQ ID NO:12)" and insert therefor --(SEQ ID NO:11)--.

Please replace the pages of the Sequence Listing with pages 47-62 of the substitute Sequence Listing submitted herewith, and renumber the subsequent pages containing the claims and the abstract accordingly.

In the Claims:

Please cancel, without prejudice to or disclaimer of the subject matter thereof, claims 1-21.

Please add the following claims 22-83:

22. An isolated antibody which specifically binds the polypeptide of SEQ ID NO:2.

23. The isolated antibody of claim 22, which specifically binds to the polypeptide of amino acids 24 to 468 of SEQ ID NO:2.

24. The isolated antibody of claim 23, which specifically binds to the polypeptide of amino acids 24 to 238 of SEQ ID NO:2.

*A¹
cont'd.*

25. The isolated antibody of claim 24, which specifically binds to the polypeptide of amino acids 132 to 221 of SEQ ID NO:2.

26. The isolated antibody of claim 24, which specifically binds to the polypeptide of amino acids 35 to 92 of SEQ ID NO:2.

27. The isolated antibody of claim 24 which specifically binds to the polypeptide of amino acids 114 to 160 of SEQ ID NO:2.

28. The isolated antibody of claim 23, which specifically binds to the polypeptide of amino acids 169 to 240 of SEQ ID NO:2.

29. The isolated antibody of claim 23, which specifically binds to the polypeptide of amino acids 239 to 264 of SEQ ID NO:2.

30. The isolated antibody of claim 23, which specifically binds to the polypeptide of amino acids 265 to 468 of SEQ ID NO:2.

31. The isolated antibody of claim 30, which specifically binds to the polypeptide of amino acids 267 to 298 of SEQ ID NO:2.

32. The isolated antibody of claim 30, which specifically binds to the polypeptide of amino acids 330 to 364 of SEQ ID NO:2.

33. The isolated antibody of claim 30, which specifically binds to the polypeptide of amino acids 391 to 404 of SEQ ID NO:2.

34. The isolated antibody of claim 30, which specifically binds to the polypeptide of amino acids 418 to 465 of SEQ ID NO:2.

35. The isolated antibody of claim 30, which specifically binds to the polypeptide of amino acids 379 to 422 of SEQ ID NO:2.

36. The isolated antibody of claim 22, wherein said antibody is polyclonal.

37. The isolated antibody of claim 22, wherein said antibody is monoclonal.

38. The isolated antibody of claim 22, wherein said antibody is chimeric.

39. The isolated antibody of claim 22, wherein said antibody is an antagonist of the polypeptide of SEQ ID NO:2.

40. The isolated antibody of claim 22, wherein said antibody is an agonist of the polypeptide of SEQ ID NO:2.

41. A composition comprising the isolated antibody of claim 22, and a carrier.

A
cont'd.

42. A method of producing the isolated antibody of claim 22, comprising:

- introducing an immunogen into an animal; and
- recovering said antibody.

43. A method of detecting the polypeptide of SEQ ID NO:2 in a biological sample comprising:

- contacting a biological sample with the isolated antibody of claim 22; and
- determining the presence or absence of said polypeptide in said biological sample.

44. An isolated antibody fragment which specifically binds to the polypeptide of SEQ ID NO:2.

45. The isolated antibody fragment of claim 44, which specifically binds to the polypeptide of amino acids 24 to 468 of SEQ ID NO:2.

46. The isolated antibody fragment of claim 45, which specifically binds to the polypeptide of amino acids 24 to 238 of SEQ ID NO:2.

47. The isolated antibody fragment of claim 46, which specifically binds to the polypeptide of amino acids 132 to 221 of SEQ ID NO:2.

48. The isolated antibody fragment of claim 46, which specifically binds to the polypeptide of amino acids 35 to 92 of SEQ ID NO:2.

O
Cont'd.

A

49. The isolated antibody fragment of claim 46, isolated antibody fragment specifically binds to the polypeptide of amino acids 114 to 160 of SEQ ID NO:2.

50. The isolated antibody fragment of claim 45, isolated antibody fragment specifically binds to the polypeptide of amino acids 169 to 240 of SEQ ID NO:2.

51. The isolated antibody fragment of claim 45, isolated antibody fragment specifically binds to the polypeptide of amino acids 239 to 264 of SEQ ID NO:2.

52. The isolated antibody fragment of claim 45, which specifically binds to the polypeptide of amino acids 265 to 468 of SEQ ID NO:2.

53. The isolated antibody fragment of claim 52, which specifically binds to the polypeptide of amino acids 267 to 298 of SEQ ID NO:2.

54. The isolated antibody fragment of claim 52, which specifically binds to the polypeptide of amino acids 330 to 364 of SEQ ID NO:2.

55. The isolated antibody fragment of claim 52, which specifically binds to the polypeptide of amino acids 391 to 404 of SEQ ID NO:2.

56. The isolated antibody fragment of claim 52, which specifically binds to the polypeptide of amino acids 418 to 465 of SEQ ID NO:2.

A
cont'd.

A

57. The isolated antibody fragment of claim 52, which specifically binds to the polypeptide of amino acids 379 to 422 of SEQ ID NO:2.

58. The isolated antibody fragment of claim 44, wherein said antibody fragment comprises an Fab fragment.

59. The isolated antibody fragment of claim 44, wherein said antibody fragment comprises an F(ab')₂ fragment.

60. The isolated antibody fragment of claim 44, wherein said antibody fragment is chimeric.

61. The isolated antibody fragment of claim 44, wherein said antibody fragment is an antagonist of the polypeptide of SEQ ID NO:2.

62. The isolated antibody fragment of claim 44, wherein said antibody fragment is an agonist of the polypeptide of SEQ ID NO:2.

63. A composition comprising the isolated antibody fragment of claim 44, and a carrier.

SEARCHED
INDEXED
MAILED
SERIALIZED
FILED

64. A method of producing the isolated antibody fragment of claim 44, comprising:

- introducing an immunogen into an animal; and
- recovering said antibody fragment.

65. A method of detecting the polypeptide of SEQ ID NO:2 in a biological sample comprising:

- contacting a biological sample with the isolated antibody fragment of claim 44; and
- determining the presence or absence of said polypeptide in said biological sample.

66. An isolated antibody which specifically binds the polypeptide encoded by the human cDNA in ATCC Deposit No. 97853.

67. The isolated antibody of claim 66, wherein said antibody is polyclonal.

68. The isolated antibody of claim 66, wherein said antibody is monoclonal.

69. The isolated antibody of claim 66, wherein said antibody is chimeric.

70. The isolated antibody of claim 66, wherein said antibody is an antagonist of the polypeptide encoded by the human cDNA in ATCC Deposit No. 97853.

71. The isolated antibody of claim 66, wherein said antibody is an agonist of the polypeptide encoded by the human cDNA in ATCC Deposit No. 97853.

Claim 1
cont'd

72. A composition comprising the isolated antibody of claim 66, and a carrier.

73. A method of producing the antibody of claim 66, comprising:

- introducing an immunogen into an animal; and
- recovering said antibody fragment.

74. A method of detecting the polypeptide encoded by the human cDNA in ATCC Deposit No. 97853 in a biological sample comprising:

- contacting a biological sample with the isolated antibody fragment of claim 66; and
- determining the presence or absence of said polypeptide in said biological sample.

75. An isolated antibody fragment which specifically binds to the polypeptide encoded by the human cDNA in ATCC Deposit No. 97853.

76. The isolated antibody fragment of claim 75, wherein said antibody fragment comprises an Fab fragment.

77. The isolated antibody fragment of claim 75, wherein said antibody fragment comprises an F(ab')₂ fragment.

78. The isolated antibody fragment of claim 75, where in said antibody fragment is chimeric.

A
1
cont'd.